NASDAQ:ARTL

Artelo Biosciences Stock Forecast, Price & News

$1.30
+0.01 (+0.78 %)
(As of 05/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$1.25
$1.38
50-Day Range
$1.13
$2.05
52-Week Range
$0.45
$3.67
Volume913,992 shs
Average Volume7.08 million shs
Market Capitalization$30.07 million
P/E RatioN/A
Dividend YieldN/A
Beta2.52
30 days | 90 days | 365 days | Advanced Chart
Receive ARTL News and Ratings via Email

Sign-up to receive the latest news and ratings for Artelo Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ARTL
CUSIPN/A
CIKN/A
Phone(760) 943-1689
Employees3
Year FoundedN/A

Sales & Book Value

Annual SalesN/A
Book Value$0.78 per share

Profitability

Net Income$-4,660,000.00

Debt

Price-To-Earnings

Miscellaneous

Market Cap$30.07 million
Next Earnings Date7/12/2021 (Estimated)
OptionableNot Optionable

Headlines

See More Headlines
Artelo Biosciences logo

About Artelo Biosciences

Artelo Biosciences, Inc. is a development stage company, which engages in discovering, licensing, developing and commercializing treatments that modulate the endocannabinoid system. The company was founded by James Manley on May 2, 2011 and is headquartered in San Diego, CA.

MarketRank

Overall MarketRank

1.57 out of 5 stars

Medical Sector

428th out of 2,043 stocks

Pharmaceutical Preparations Industry

200th out of 771 stocks

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Artelo Biosciences (NASDAQ:ARTL) Frequently Asked Questions

Is Artelo Biosciences a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Artelo Biosciences in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Artelo Biosciences stock.
View analyst ratings for Artelo Biosciences
or view top-rated stocks.

What stocks does MarketBeat like better than Artelo Biosciences?

Wall Street analysts have given Artelo Biosciences a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Artelo Biosciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Artelo Biosciences' next earnings date?

Artelo Biosciences is scheduled to release its next quarterly earnings announcement on Monday, July 12th 2021.
View our earnings forecast for Artelo Biosciences
.

How were Artelo Biosciences' earnings last quarter?

Artelo Biosciences, Inc. (NASDAQ:ARTL) posted its earnings results on Monday, April, 12th. The company reported ($0.03) EPS for the quarter, topping the Zacks' consensus estimate of ($0.12) by $0.09.
View Artelo Biosciences' earnings history
.

How has Artelo Biosciences' stock been impacted by Coronavirus (COVID-19)?

Artelo Biosciences' stock was trading at $1.01 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ARTL shares have increased by 28.7% and is now trading at $1.30.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for ARTL?

2 brokers have issued 12 month price targets for Artelo Biosciences' stock. Their forecasts range from $7.00 to $7.00. On average, they anticipate Artelo Biosciences' share price to reach $7.00 in the next twelve months. This suggests a possible upside of 438.5% from the stock's current price.
View analysts' price targets for Artelo Biosciences
or view top-rated stocks among Wall Street analysts.

Who are Artelo Biosciences' key executives?

Artelo Biosciences' management team includes the following people:
  • Gregory D. Gorgas, President, CEO, CFO, Secretary & Treasurer
  • Randy Schreckhise, Vice President-Finance & Operations
  • Steven D. Reich, Chief Medical Officer
  • Andy Yates, Chief Scientific Officer & Senior Vice President
  • Peter O’Brien, Senior Vice President-European Operations

Who are some of Artelo Biosciences' key competitors?

What other stocks do shareholders of Artelo Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Artelo Biosciences investors own include NVIDIA (NVDA), VBI Vaccines (VBIV), Provention Bio (PRVB), Sorrento Therapeutics (SRNE), ADMA Biologics (ADMA), Flexion Therapeutics (FLXN), OPKO Health (OPK), Overstock.com (OSTK), Allena Pharmaceuticals (ALNA) and Advanced Micro Devices (AMD).

What is Artelo Biosciences' stock symbol?

Artelo Biosciences trades on the NASDAQ under the ticker symbol "ARTL."

Who are Artelo Biosciences' major shareholders?

Artelo Biosciences' stock is owned by a variety of institutional and retail investors. Top institutional investors include LVM Capital Management Ltd. MI (0.13%). Company insiders that own Artelo Biosciences stock include Connie Matsui and Gregory D Gorgas.
View institutional ownership trends for Artelo Biosciences
.

Which major investors are buying Artelo Biosciences stock?

ARTL stock was purchased by a variety of institutional investors in the last quarter, including LVM Capital Management Ltd. MI. Company insiders that have bought Artelo Biosciences stock in the last two years include Connie Matsui, and Gregory D Gorgas.
View insider buying and selling activity for Artelo Biosciences
or or view top insider-buying stocks.

How do I buy shares of Artelo Biosciences?

Shares of ARTL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Artelo Biosciences' stock price today?

One share of ARTL stock can currently be purchased for approximately $1.30.

How much money does Artelo Biosciences make?

Artelo Biosciences has a market capitalization of $30.07 million.

How many employees does Artelo Biosciences have?

Artelo Biosciences employs 3 workers across the globe.

What is Artelo Biosciences' official website?

The official website for Artelo Biosciences is www.artelobio.com.

Where are Artelo Biosciences' headquarters?

Artelo Biosciences is headquartered at 888 Prospect Street Suite 210, La Jolla CA, 92037.

How can I contact Artelo Biosciences?

Artelo Biosciences' mailing address is 888 Prospect Street Suite 210, La Jolla CA, 92037. The company can be reached via phone at (760) 943-1689 or via email at [email protected]


This page was last updated on 5/6/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.